335 related articles for article (PubMed ID: 16524568)
1. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
Dzamitika SA; Falcão CA; de Oliveira FB; Marbeuf C; Garnier-Suillerot A; Demicheli C; Rossi-Bergmann B; Frézard F
Chem Biol Interact; 2006 Apr; 160(3):217-24. PubMed ID: 16524568
[TBL] [Abstract][Full Text] [Related]
2. Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity.
Borborema SE; Osso Junior JA; Andrade Junior HF; Nascimento Nd
Rev Soc Bras Med Trop; 2016 Apr; 49(2):196-203. PubMed ID: 27192589
[TBL] [Abstract][Full Text] [Related]
3. Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect.
Abamor ES; Allahverdiyev AM; Bagirova M; Rafailovich M
Acta Trop; 2017 May; 169():30-42. PubMed ID: 28111133
[TBL] [Abstract][Full Text] [Related]
4. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
[TBL] [Abstract][Full Text] [Related]
5. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
[TBL] [Abstract][Full Text] [Related]
6. Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate.
Frézard F; Demicheli C; Ferreira CS; Costa MA
Antimicrob Agents Chemother; 2001 Mar; 45(3):913-6. PubMed ID: 11181379
[TBL] [Abstract][Full Text] [Related]
7. Antileishmanial Activity of 2-Methoxy-4H-spiro-[naphthalene-1,2'-oxiran]-4-one (Epoxymethoxy-lawsone): A Promising New Drug Candidate for Leishmaniasis Treatment.
Oliveira LFG; Souza-Silva F; de Castro Côrtes LM; Cysne-Finkelstein L; de Souza Pereira MC; de Oliveira Junior FO; Pinho RT; Corte Real S; Bourguignon SC; Ferreira VF; Alves CR
Molecules; 2018 Apr; 23(4):. PubMed ID: 29642584
[TBL] [Abstract][Full Text] [Related]
8. Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum.
Moreira VR; de Jesus LCL; Soares RP; Silva LDM; Pinto BAS; Melo MN; Paes AMA; Pereira SRF
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320726
[TBL] [Abstract][Full Text] [Related]
9. Antimony oxidation states in antileishmanial drugs.
Franco MA; Barbosa AC; Rath S; Dorea JG
Am J Trop Med Hyg; 1995 May; 52(5):435-7. PubMed ID: 7771610
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
Carrió J; Portús M
BMC Pharmacol; 2002 May; 2():11. PubMed ID: 12019027
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of antimony complexes of yeast mannan and mannan derivatives and their effect on Leishmania-infected macrophages.
Cantos G; Barbieri CL; Iacomini M; Gorin PA; Travassos LR
Biochem J; 1993 Jan; 289 ( Pt 1)(Pt 1):155-60. PubMed ID: 8424752
[TBL] [Abstract][Full Text] [Related]
12. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG
J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185
[TBL] [Abstract][Full Text] [Related]
13. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.
Demicheli C; Ochoa R; da Silva JB; Falcão CA; Rossi-Bergmann B; de Melo AL; Sinisterra RD; Frézard F
Antimicrob Agents Chemother; 2004 Jan; 48(1):100-3. PubMed ID: 14693525
[TBL] [Abstract][Full Text] [Related]
14. Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia.
Fernández OL; Diaz-Toro Y; Ovalle C; Valderrama L; Muvdi S; Rodríguez I; Gomez MA; Saravia NG
PLoS Negl Trop Dis; 2014 May; 8(5):e2871. PubMed ID: 24853871
[TBL] [Abstract][Full Text] [Related]
15. Nanoscaled hydrated antimony (V) oxide as a new approach to first-line antileishmanial drugs.
Franco AM; Grafova I; Soares FV; Gentile G; Wyrepkowski CD; Bolson MA; Sargentini É; Carfagna C; Leskelä M; Grafov A
Int J Nanomedicine; 2016; 11():6771-6780. PubMed ID: 28008252
[TBL] [Abstract][Full Text] [Related]
16. Characterization of reactions of antimoniate and meglumine antimoniate with a guanine ribonucleoside at different pH.
dos Santos Ferreira C; de Castro Pimenta AM; Demicheli C; Frézard F
Biometals; 2006 Oct; 19(5):573-81. PubMed ID: 16937264
[TBL] [Abstract][Full Text] [Related]
17. Pentavalent antimonials: new perspectives for old drugs.
Frézard F; Demicheli C; Ribeiro RR
Molecules; 2009 Jun; 14(7):2317-36. PubMed ID: 19633606
[TBL] [Abstract][Full Text] [Related]
18. Complexes of different nitrogen donor heterocyclic ligands with SbCl3 and PhSbCl2 as potential antileishmanial agents against Sb(III)-sensitive and -resistant parasites.
Lizarazo-Jaimes EH; Reis PG; Bezerra FM; Rodrigues BL; Monte-Neto RL; Melo MN; Frézard F; Demicheli C
J Inorg Biochem; 2014 Mar; 132():30-6. PubMed ID: 24412095
[TBL] [Abstract][Full Text] [Related]
19. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action.
Sereno D; Cavaleyra M; Zemzoumi K; Maquaire S; Ouaissi A; Lemesre JL
Antimicrob Agents Chemother; 1998 Dec; 42(12):3097-102. PubMed ID: 9835497
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
